The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Initial results of the phase III BOSTON study
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, gives an update on data from the BOSTON study (NCT03110562) – the first phase III study to evaluate the clinical benefit of selinexor with bortezomib and dexamethasone (SVd) for relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
